CRISPR-Cas9 Targeting of Specific Mutations in Lung Cancer With Supporting In Vivo Data
- Optimising CRISPR/Cas9-loaded LNPs as a novel therapeutic strategy to target specific mutations in lung cancer
- Presenting in vitro and in vivo data demonstrating editing efficiency, safety, and the therapeutic potential in preclinical models
- Discussing the translational implications for moving CRISPR-based lung cancer therapies toward the clinic